Jian Han

Key Laboratory For Drug Screening Technology Of Shandong Academy Of Sciences
Jinan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

The Multitalented Marvels: Exploring the Versatile Potential of Natural Products in Osteosarcoma Treatment.

The Multitalented Marvels: Exploring the Versatile Potential of Natural Products in Osteosarcoma Treatment.

Journal: Cancer informatics

Published: April 19, 2026

Robust fault-tolerant control of nonlinear switched stochastic systems based on functional observers.

Robust fault-tolerant control of nonlinear switched stochastic systems based on functional observers.

Journal: ISA transactions

Published: January 24, 2026

Fault-tolerant control based on multi-reduced-order intermediate observers for multi-agent systems with a leader of unknown input.

Fault-tolerant control based on multi-reduced-order intermediate observers for multi-agent systems with a leader of unknown input.

Journal: ISA transactions

Published: January 08, 2026

Integrated design of fault estimation and fault-tolerant control of the linear system.

Integrated design of fault estimation and fault-tolerant control of the linear system.

Journal: ISA transactions

Published: August 09, 2025

Recent advances in biomaterials for osteosarcoma treatment.

Recent advances in biomaterials for osteosarcoma treatment.

Journal: Regenerative biomaterials

Published: March 28, 2025

Molecular mechanism of modified KAT2A-mediated histone succinylation in asthma through inhibition of ferroptosis.

Molecular mechanism of modified KAT2A-mediated histone succinylation in asthma through inhibition of ferroptosis.

Journal: Clinics (Sao Paulo, Brazil)

Published: February 20, 2025

NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.

NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.

Journal: Cancer letters

Published: November 30, 2023

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway.

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway.

Journal: Journal of bone oncology

Published: November 21, 2023

AP003352.1/miR-141-3p axis enhances the proliferation of osteosarcoma by LPAR3.

AP003352.1/miR-141-3p axis enhances the proliferation of osteosarcoma by LPAR3.

Journal: PeerJ

Published: April 19, 2023

NUCKS1, a LINC00629-upregulated gene, facilitated osteosarcoma progression and metastasis by elevating asparagine synthesis.

NUCKS1, a LINC00629-upregulated gene, facilitated osteosarcoma progression and metastasis by elevating asparagine synthesis.

Journal: Cell death & disease

Published: February 27, 2023

LINC00629 protects osteosarcoma cell from ER stress-induced apoptosis and facilitates tumour progression by elevating KLF4 stability.

LINC00629 protects osteosarcoma cell from ER stress-induced apoptosis and facilitates tumour progression by elevating KLF4 stability.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 11, 2022

Pleckstrin homology-like domain family A, member 3, a miR-19a-3p-regulated gene, suppresses tumor growth in osteosarcoma by downregulating the Akt pathway.

Pleckstrin homology-like domain family A, member 3, a miR-19a-3p-regulated gene, suppresses tumor growth in osteosarcoma by downregulating the Akt pathway.

Journal: Bioengineered

Published: February 03, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026